Training in Pharmacology of Antineoplastic Agents

描述(申请人提供)：医学肿瘤学部，药学院，和骨髓移植计划赞助一个跨学科的博士后培训项目“抗肿瘤药物的临床药理学”。该培训计划的目标是为个人提供开发抗肿瘤药物、评估其特性、设计临床研究以及将这些药物通过监管机构进入国家试验所需的复杂技能。参与此次培训的导师认为，受过化疗药物实际评估培训的科学家有重要需求，以促进这些药物从实验室工作台到床边的移动。 该计划包括2-3年的基础实验室研究培训、必修核心课程、可供选择的系列讲座和选修课。一个由三个合作单位的主任组成的执行委员会将管理它，一个由三名教员组成的导师委员会将监督学生的进步。学员将被要求撰写一份NIH风格的RO-1，在当地举办研究研讨会，参加全国会议，并在同行评议的期刊上发表文章。项目总监将每年对受训人员进行评估。 这笔培训补助金的头四年非常成功。在完成该项目的8名学员中，有3人加入了学术医学中心，3人进入了行业抗癌药物开发。40%的受训人员是女性。一名西班牙裔男性和几乎相同数量的医学博士和博士接受了培训。培训助学金教授了两门新的核心课程，一门是抗癌药物药理学，另一门是癌症生物学，这两门课程成为医学院课程的一部分。 这一独特的培训计划提供了一个互动环境，参与抗肿瘤药物开发所有阶段的医学博士和博士将对个人进行必要的临床前和临床科学培训，将抗癌药物从试验台带到床边。

DESCRIPTION (provided by applicant): The Division of Medical Oncology, School of Pharmacy, and the Bone Marrow Transplant Program sponsor an interdisciplinary postdoctoral training program in the "Clinical Pharmacology of Antineoplastic Agents." The goal of this training program is to provide individuals with the complex skills necessary to develop antineoplastic agents, evaluate their properties, design clinical studies, and move these agents through the regulatory agencies into national trials. The preceptors involved in this training believe that there is an important need for scientists who are trained in the practical evaluation of chemotherapeutic agents to facilitate the movement of these agents from the laboratory bench to the bedside. The program includes 2-3 years of basic laboratory research training, required core courses, available lecture series and elective courses. An Executive Committee consisting of the directors of the three cooperating units will administer it, and a Mentor's Committee of three faculty members will monitor student progress. Trainees will be required to write a NIH style RO-1, give local research seminars, attend national meetings, and publish articles in peer-reviewed journals. The trainees will be evaluated on a yearly basis by the Program Director. The first four years of this training grant have been extremely successful. Of the eight trainees that have completed the program, three have joined academic medical centers and three have gone into cancer drug development in industry. Forty percent of the trainees have been women. One Hispanic male and almost equal numbers of M.D.s and Ph.D.s were trained. The training grant faculty taught two new core courses, one in cancer drug pharmacology and the other in cancer biology that became part of the Medical School curriculum. This unique training program provides an interactive environment in which M.D.s and Ph.Ds involved in all phases of antineoplastic agent development will train individuals in the preclinical and clinical science necessary to take anticancer agents from the bench to the bedside.